Last Updated: September 27, 2026

Patent: 7,655,226

✉ Email this page to a colleague

Summary for Patent: 7,655,226

Title:	Treatment of Pompe's disease
Abstract:	The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient.
Inventor(s):	Johannes B. M. M. van Bree, Edna H. G. Venneker, David P. Meeker
Assignee:	Genzyme Therapeutic Products LP
Application Number:	US12/012,003
Patent Claims:	see list of patent claims

Details for Patent 7,655,226

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	28-Apr-06	⤷ Start Trial	2028-01-30
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	24-May-10	⤷ Start Trial	2028-01-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,655,226

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Austria	E240637	⤷ Start Trial
Austria	E410506	⤷ Start Trial
Australia	3113700	⤷ Start Trial
Australia	6789096	⤷ Start Trial
Australia	734953	⤷ Start Trial
Belgium	2018C038	⤷ Start Trial
Canada	2353522	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.